Preferred
(EDT)
Other
Therapeutics I: Ex Vivo Editing
The Future is Allogeneic - Translating a CRISPR Platform into Gene-Edited Cell Therapies
10:00 AM - 10:25 AM EST
Tuesday, March 9, 2021Speaker
Rachel Haurwitz, PhD
Caribou Biosciences, Inc.
Therapeutics I: Ex Vivo Editing
Genome Editing of Blood Cells to Cure Disease
10:25 AM - 10:50 AM EST
Tuesday, March 9, 2021Speaker
Matthew Porteus, MD, PhD
Stanford University School of Medicine
Therapeutics I: Ex Vivo Editing
T-Cell Gene Editing for Cancer Immunotherapy
10:50 AM - 11:15 AM EST
Tuesday, March 9, 2021Speaker
Chiara Bonini, MD
Vita-Salute San Raffaele University
Therapeutics I: Ex Vivo Editing
Coffee Break
11:15 AM - 11:35 AM EST
Tuesday, March 9, 2021Therapeutics I: Ex Vivo Editing
An Adenine Base Editing Strategy for the Treatment of Sickle Cell Disease by Elimination of the Pathogenic Globin Protein
11:35 AM - 12:00 PM EST
Tuesday, March 9, 2021Speaker
Nicole Gaudelli, PhD
Beam Therapeutics
Therapeutics I: Ex Vivo Editing
[NOT AVAILABLE ON DEMAND] Short Talk: Knockout of NKG2A by CRISPR in Human NK Cells Enhance their Cytotoxic Activity Against Solid Tumors
12:00 PM - 12:15 PM EST
Tuesday, March 9, 2021Speaker
Delphine Guipouy, PhD
CHU Sainte Justine Research Center
Therapeutics I: Ex Vivo Editing
Short Talk: Fast and Efficient Generation of TRAC-integrated CAR T Cells without Viruses
12:15 PM - 12:30 PM EST
Tuesday, March 9, 2021Speaker
Dimitrios Wagner, MD
Charité - Universitätsmedizin Berlin
Therapeutics I: Ex Vivo Editing
Short Talk: Optimizing Stem Cell Lines for in vitro-derived Beta Cell Therapeutics via Genome-wide CRISPR Knock-out Screening
12:30 PM - 12:45 PM EST
Tuesday, March 9, 2021Speaker
Adrian Veres, PhD
Harvard University
Therapeutics I: Ex Vivo Editing
Short Talk: Expanding the Scope of Marker-Free Selection for CRISPR-Driven Genome Editing in Human Cells
12:45 PM - 1:00 PM EST
Tuesday, March 9, 2021Speaker
Sébastien Levesque, MS
CHU de Québec - Université Laval
Therapeutics I: Ex Vivo Editing
